Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

CBRNE - Botulism Workup

  • Author: Peter P Taillac, MD; Chief Editor: Duane C Caneva, MD, MSc  more...
 
Updated: Apr 21, 2015
 

Laboratory Studies

For laboratory confirmation, before treatment with antitoxin, obtain 10-15 mL of serum, 25-50 g of feces, and possibly 25-50 mL of fluid from gastric aspiration. Collect and refrigerate similar quantities of suspected food samples for testing. In constipated patients, a gentle saline enema may be required to obtain fecal specimens.

Label each specimen container with the patient's name, specimen type, date of collection, and medications being received, and send it to a state health department-approved reference laboratory in insulated cold packs. Contact your local health department for specific instructions.

Confirmation of the organism and/or toxin and toxin typing is obtained in almost 75% of cases. Early cases are more likely to be diagnosed by toxin assay, whereas later ones are more likely to have a positive culture. Laboratory confirmation of toxin presence is via a mouse bioassay, and identification of the toxin type is performed by a mouse toxin neutralization test.

Food-borne botulism

For food-borne botulism, toxin is found in serum samples 39% of the time and in stools 24% of the time. Organisms are found in cultures of stool samples 55% of the time. Stool cultures generally are more sensitive than toxin detection for specimens obtained later (> 3 d postingestion) in the course of illness.

An experimental test strip has been developed that enables field detection of type A and B toxins in foods.[6] A cell-based assay that uses a fluorescence reporter construct expressed in a neuronal cell model to study toxin activity in situ was able to detect as little as 100 pM botulism A activity in living cells, and is being evaluated for use in food matrices.[7]

Infant botulism

In patients whom infant botulism is suspected, stools and enema fluids (with minimal water added to limit dilution of toxin) are the specimens of choice, as serum is only rarely toxin positive. One also may wish to culture possible sources of clostridia, such as honey or house dust.

Other botulism forms and laboratory tests

Wound botulism: Wound botulism may be identified by detection of toxin in serum or by culture of wound specimens.

Adult colonization botulism: Organisms may be detected in stool and toxin in serum for up to 119 days following the onset of symptoms.

New methods of detection: In vitro methods of detection, including polymerase chain reaction (PCR) – based detection of clostridial genes and enzyme-linked immunoassay (ELISA) identification of toxin, have been developed. However, these methods are not widely available outside of research institutions.

 
 
Contributor Information and Disclosures
Author

Peter P Taillac, MD Clinical Professor of Surgery, Division of Emergency Medicine, University of Utah Health Sciences Center

Peter P Taillac, MD is a member of the following medical societies: American College of Emergency Physicians, National Association of EMS Physicians, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Joseph Kim, MD Chairman, Department of Emergency Medicine, Western Medical Center; Clinical Instructor, University of California, Irvine, School of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Barry J Sheridan, DO Chief Warrior in Transition Services, Brooke Army Medical Center

Barry J Sheridan, DO is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Duane C Caneva, MD, MSc Senior Medical Advisor to Customs and Border Protection, Department of Homeland Security (DHS) Office of Health Affairs; Federal Co-Chair, Health, Medical, Responder Safety Subgroup, Interagency Board (IAB)

Disclosure: Nothing to disclose.

Additional Contributors

Edward Bessman, MD, MBA Chairman and Clinical Director, Department of Emergency Medicine, John Hopkins Bayview Medical Center; Assistant Professor, Department of Emergency Medicine, Johns Hopkins University School of Medicine

Edward Bessman, MD, MBA is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

References
  1. Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis. 2004 Sep. 10(9):1606-11. [Medline]. [Full Text].

  2. Centers for Disease Control and Preventions. CDC U.S.National Botulism Surveillance Summary. Available at http://www.cdc.gov/nationalsurveillance/botulism-surveillance.html. Accessed: December 22, 2014.

  3. McCroskey LM, Hatheway CL. Laboratory findings in four cases of adult botulism suggest colonization of the intestinal tract. J Clin Microbiol. 1988 May. 26(5):1052-4. [Medline].

  4. Mechem CC, Walter FG. Wound botulism. Vet Hum Toxicol. 1994 Jun. 36(3):233-7. [Medline].

  5. Nystrom SC, Wells EV, Pokharna HS, et al. Botulism toxemia following laparoscopic appendectomy. Clin Infect Dis. 2012 Feb 15. 54(4):e32-4. [Medline].

  6. Ching KH, Lin A, McGarvey JA, Stanker LH, Hnasko R. Rapid and selective detection of botulinum neurotoxin serotype-A and -B with a single immunochromatographic test strip. J Immunol Methods. 2012 Jun 29. 380(1-2):23-9. [Medline].

  7. Basavanna U, Muruvanda T, Brown EW, Sharma SK. Development of a Cell-Based Functional Assay for the Detection of Clostridium botulinum Neurotoxin Types A and E. Int J Microbiol. 2013. 2013:593219. [Medline]. [Full Text].

  8. Kiris E, Burnett JC, Kane CD, Bavari S. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem. 2014. 14(18):2044-61. [Medline].

  9. Arnon SS, Schechter R, Inglesby TV. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001 Feb 28. 285(8):1059-70. [Medline].

  10. Bigalke H, Rummel A. Medical aspects of toxin weapons. Toxicology. 2005 Oct 30. 214(3):210-20. [Medline].

  11. Centers for Disease Control and Prevention. Botulism associated with commercially canned chili sauce--Texas and Indiana, July 2007. MMWR. Aug 3, 2007. 56(30):767-9. [Medline].

  12. Dunbar EM. Botulism. J Infect. 1990 Jan. 20(1):1-3. [Medline].

  13. Fox CK, Keet CA, Strober JB. Recent advances in infant botulism. Pediatr Neurol. 2005 Mar. 32(3):149-54. [Medline].

  14. Freedman M, Armstrong RM, Killian JM. Botulism in a patient with jejunoileal bypass. Ann Neurol. 1986 Nov. 20(5):641-3. [Medline].

  15. Goonetilleke A, Harris JB. Clostridial neurotoxins. J Neurol Neurosurg Psychiatry. 2004 Sep. 75 Suppl 3:iii35-9. [Medline].

  16. Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 1995. 195:55-75. [Medline].

  17. Horowitz BZ. Botulinum toxin. Crit Care Clin. 2005 Oct. 21(4):825-39, viii. [Medline].

  18. Horowitz, B. Zane. The ripe olive scare and hotel Loch Maree tragedy: Botulism under glass in the 1920’s. Clinical Toxicology. 2011. 49:345-347.

  19. Mandell GL, Bennett JE, Dolin R. Clostridium botulinum. Principles and Practice of Infectious Diseases. 4th ed. 1995. 2178.

  20. Marks JD. Medical aspects of biologic toxins. Anesthesiol Clin North America. 2004 Sep. 22(3):509-32, vii. [Medline].

  21. Mcnally RE, Morrison MB, Berndt JE, et al. Effectiveness of medical defense interventions against predicted battlefield levels of botulinum toxin A. 1994.

  22. Park JB, Simpson LL. Progress toward development of an inhalation vaccine against botulinum toxin. Expert Rev Vaccines. 2004. 3(4):477-87. [Medline].

  23. Schmidt RD, Schmidt TW. Infant botulism: a case series and review of the literature. J Emerg Med. 1992 Nov-Dec. 10(6):713-8. [Medline].

  24. Shukla HD, Sharma SK. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005. 31(1):11-8. [Medline].

  25. Smith, LA; Rusnak, JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol. 2007. 27(4):303-18. [Medline].

  26. Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med. 2004 May-Jun. 4(3):258-61. [Medline].

  27. Underwood K, Rubin S, Deakers T, Neuth C. Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Childrens Hospital Los Angeles. Pediatrics. Dec 2007. 120(6):e1380-5. [Medline].

  28. Weber JT, Hoeprich PD, et al. Botulism. Jordan MC, et al, eds. Infectious Diseases. 5th ed. 1994. 1185.

  29. Wenham TN. Botulism: a rare complication of injecting drug use. Emerg Med J. 2008 Jan. 25(1):55-6. [Medline].

  30. World Health Organization. Outbreak news. Botulism, Thailand. Wkly Epidemiol Rec. 2006 Mar 31. 81(13):118. [Medline].

 
Previous
Next
 
Courtesy of Arnon SS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001 Apr 25;285:1059.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.